Dishman Carbogen Amcis Says Results of Successful Clinical Research Study
Dishman Carbogen Amcis announced the positive results of partnering with Boston University School of Medicine on a clinical research study that reveals a positive response for vitamin D deficiency / insufficiency in patients with COVID-19.
Dishman Carbogen Amcis, a global pharmaceutical industry outsourcing partner, reported positive results from a new clinical research study that showed oral 25-hydroxyvitamin D3 (Calcifediol) was able to correct vitamin D deficiency / insufficiency in patients with COVID-19 and that it resulted in improved immune function by increasing the percentages of lymphocytes in the blood.
The research was overseen by Tehran University of Medical Sciences and Boston University School of Medicine and supported in part by a grant from Dishman Carbogen Amcis wholly owned subsidiary Carbogen Amcis BV.
The study showed that patients receiving the 25-hydroxy metabolite had a clearly more favorable development of their immunological defense against COVID-19 compared to those given a placebo. Thus, the dosage of the metabolite significantly increased the blood levels as well as the comparative percentage of lymphocytes in the blood, i.e. a reduced neutrophils / blood lymphocytes ratio.
On a consolidated basis, the company’s net profit jumped 51.6% to Rs 11.19 crore on a 4.4% increase in net sales to Rs 458.90 crore in the second quarter of September 2021 compared to second quarter of September 2020.
Shares of Dishman Carbogen Amcis rose 0.88% to Rs 247.45 on BSE. Dishman Carbogen Amcis provides a portfolio of drug development and marketing services to the pharmaceutical and biopharmaceutical industries at all stages of drug development.
Powered by Capital Market – Live News
(This story was not edited by Business Standard staff and is auto-generated from a syndicated feed.)